Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New vaccine platform may fight infections with causes from influenza to bioterrorism

24.11.2005


Researchers from Children’s Hospital of Pittsburgh, University of Pittsburgh and Louisiana State University report findings in Journal of Clinical Investigation

The development of effective vaccines for people with compromised immune systems may be feasible after all, according to a team of researchers, who demonstrated their approach could protect against pneumocystis pneumonia in mice lacking the same population of immune cells that HIV destroys in humans. The vaccine platform developed by Children’s Hospital of Pittsburgh researchers, working in collaboration with researchers from the University of Pittsburgh and Louisiana State University, suggests that the immune system can be primed to ward off other infections as well, such as those caused by the flu, smallpox or exposure to anthrax, even in patients who have the highest risk for infection.

Reporting in the Journal of Clinical Investigation, Jay K. Kolls, MD, division chief of Pediatric Pulmonology, Laboratory of Lung Immunology and Host Defense at Children’s Hospital of Pittsburgh, and professor of Pediatrics and Immunology at the University of Pittsburgh School of Medicine, and co-authors describe how their vaccine consisting of a specific antigen to pneumocystis and a molecule normally expressed on activated T-cells of the immune system offers protection from infection even in the absence of essential immune cells.



Pneumocystis is a common and very serious infection in people with deficient function of CD4+ T-cells, such as patients with transplanted organs, HIV and children with leukemia. Without normal reservoirs of these particular T-cells that are key to immune responses, these patients are unable to stave off an infection that in most people causes, at most, a bad cold.

The findings are being published in the December 1 issue of the journal. The manuscript will be available online after 5 p.m. Nov. 23, 2005, at www.jci.org.

"In addition to protection against pneumocystis, our vaccine platform may be effective in preventing viral illnesses such as influenza, in high-risk, immune-deficient individuals," Dr. Kolls said. "This new technology opens up the possibility that therapeutic vaccine response can be achieved in populations of patients who face the greatest risk – children, the immunosuppressed and the elderly.

Although not discussed in the paper, Dr. Kolls says the vaccine approach is worth investigating its potential for offering protection against weaponized agents, such as anthrax.

In mice depleted of CD4+ T cells, which are essential for signaling other cells and for producing antigen-specific antibodies, the vaccine strategy provided protection against pneumocystis. Importantly, this vaccine strategy was able to bypass the need for T cells.

A series of experiments helped identify the two key components of the experimental DNA vaccine, so called because it has only the molecular signatures of these constructs: the molecule used by activated CD4+ T cells to signal production of antibodies, and importantly, the specific fragment of pneumocystis that receptors on these antibodies recognize.

The researchers first identified as key CD40L, a molecule expressed on activated CD4+ T cells that in turn signals other cells, including B cells, to produce antibodies against the pathogen. But antibodies rely on other cells, such as dendritic cells, to capture the antigen and advertise their bounty, which they do by displaying an antigen fragment on their cell surface. Antibodies see this antigen fragment as a mug shot of sorts, and when they recognize the same fragment expressed on the on the infecting organism the antibodies give phagocytic cells the OK to consume, or eliminate, the pathogen. Through their studies, the researchers discovered a particularly potent fragment of pneumocystis, the kexin molecule, which when isolated yielded greater antibody response than pneumocystis as a whole.

In perhaps the most significant experiments the researchers conducted, mice depleted of CD4+ T cells received the combination CD40L-kexin vaccine in three doses administered three weeks apart. Three weeks later, they were infected with pneumocystis. Upon examination, the vaccinated mice had significantly less organism in their lungs. According to the researchers, nearly 100 percent (999.999 percent) of the invading pneumocystis was thwarted by the vaccine-induced antibody-mediated process, compared to about 20 percent in animals that had not been vaccinated.

The number of people with compromised immune systems continues to rise, a population that cannot be protected against polio, the flu and other infectious agents with existing vaccines that depend on a normal T-cell response. As such, the researchers were motivated to develop CD4+ T-cell–independent therapeutic strategies to meet this growing need.

"While we’ll need to replicate these findings in larger animal models, our studies indicate it may be feasible to develop vaccines for bioterrorism agents and transplant patients, as well as high-risk individuals who have defective CD4+ T-cell function," Dr. Kolls said. "We are excited about the results because they indicate that we can engineer a vaccine to create a new protection for those who are immunosuppressed."

In addition to Dr. Kolls, other authors include Mingquan Zheng, M.D.; Chad Steele, Ph.D., and Florencia McAllister, M.D., all of Children’s Hospital and the department of pediatrics, University of Pittsburgh School of Medicine; Corrine Kliment, Christopher Crowe and Rekha R. Rapaka, University of Pittsburgh School of Medicine M.D.-Ph.D. students; Karen A. Norris, Ph.D., department of immunology, University of Pittsburgh School of Medicine; and Alistair J. Ramsey, Ph.D.; Myles B. Robichaux, M.S., Judd E. Shellito, M.D., and Paul Schwarzenberger, M.D., from Louisiana State University.

Melanie Finnigan | EurekAlert!
Further information:
http://www.chp.edu
http://www.jci.org

More articles from Life Sciences:

nachricht Cells communicate in a dynamic code
19.02.2018 | California Institute of Technology

nachricht Studying mitosis' structure to understand the inside of cancer cells
19.02.2018 | Biophysical Society

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

Im Focus: Hybrid optics bring color imaging using ultrathin metalenses into focus

For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.

But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...

Im Focus: Stem cell divisions in the adult brain seen for the first time

Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.

The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...

Im Focus: Interference as a new method for cooling quantum devices

Theoretical physicists propose to use negative interference to control heat flow in quantum devices. Study published in Physical Review Letters

Quantum computer parts are sensitive and need to be cooled to very low temperatures. Their tiny size makes them particularly susceptible to a temperature...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Contacting the molecular world through graphene nanoribbons

19.02.2018 | Materials Sciences

When Proteins Shake Hands

19.02.2018 | Materials Sciences

Cells communicate in a dynamic code

19.02.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>